DE69028694T2 - Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden - Google Patents

Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden

Info

Publication number
DE69028694T2
DE69028694T2 DE69028694T DE69028694T DE69028694T2 DE 69028694 T2 DE69028694 T2 DE 69028694T2 DE 69028694 T DE69028694 T DE 69028694T DE 69028694 T DE69028694 T DE 69028694T DE 69028694 T2 DE69028694 T2 DE 69028694T2
Authority
DE
Germany
Prior art keywords
bone marrow
oligonucleotides
preparations
treating cancer
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69028694T
Other languages
English (en)
Other versions
DE69028694D1 (de
Inventor
Larry Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE69028694D1 publication Critical patent/DE69028694D1/de
Application granted granted Critical
Publication of DE69028694T2 publication Critical patent/DE69028694T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
DE69028694T 1989-02-15 1990-01-24 Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden Expired - Fee Related DE69028694T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/311,096 US5087617A (en) 1989-02-15 1989-02-15 Methods and compositions for treatment of cancer using oligonucleotides
PCT/US1990/000472 WO1990009180A1 (en) 1989-02-15 1990-01-24 Methods and compositions for treatment of cancer using oligonucleotides

Publications (2)

Publication Number Publication Date
DE69028694D1 DE69028694D1 (de) 1996-10-31
DE69028694T2 true DE69028694T2 (de) 1997-05-15

Family

ID=23205390

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69028694T Expired - Fee Related DE69028694T2 (de) 1989-02-15 1990-01-24 Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden

Country Status (10)

Country Link
US (1) US5087617A (de)
EP (1) EP0458829B1 (de)
JP (1) JPH04505752A (de)
AT (1) ATE143265T1 (de)
AU (1) AU635002B2 (de)
CA (1) CA2046916C (de)
DE (1) DE69028694T2 (de)
DK (1) DK0458829T3 (de)
ES (1) ES2094148T3 (de)
WO (1) WO1990009180A1 (de)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US6677312B1 (en) 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US6800617B1 (en) 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US7238673B2 (en) * 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
CA2025181A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting fungi
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5989849A (en) * 1991-05-09 1999-11-23 Temple University Of The Commonwealth System Of Higher Education Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5582986A (en) * 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
DE69230223T2 (de) * 1991-06-14 2000-02-17 Isis Pharmaceuticals Inc Antisense-oligonukleotid-inhibition des ras-gen
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
EP1271146A1 (de) * 1991-08-23 2003-01-02 Board Of Regents Of The University Of Nebraska Verfahren und Zusammensetzungen für zelluläre Reprogrammierung
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5359044A (en) * 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DE4142452A1 (de) * 1991-12-18 1993-06-24 Max Planck Gesellschaft Mittel zur stimulierung der teilungsaktivitaet tierischer zellen
EP0644889A4 (de) * 1991-12-24 1996-01-10 Isis Pharmaceuticals Inc ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION VON-g(b)-AMYLOID.
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
CA2134670A1 (en) * 1992-04-30 1993-11-11 Dennis R. Roop Constitutive and inducible epidermal vector systems
US5958764A (en) * 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
US6175000B1 (en) * 1992-09-30 2001-01-16 The Salk Institute For Biological Studies Nucleic acids encoding human trithorax protein
AU5136693A (en) * 1992-10-01 1994-04-26 Thomas Jefferson University Antisense oligonucleotides to b myb proto-oncogene
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
EP0689460A4 (de) * 1993-02-19 1996-11-13 Isis Pharmaceuticals Inc Cyclobutyl antisinn-oligonukleotide, herstellungsmethoden und verwendung davon
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
WO1994021791A1 (en) * 1993-03-16 1994-09-29 Johanna Eugenie Bergmann Agents for the prevention and treatment of breast cancer
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
WO1994028720A1 (en) * 1993-06-11 1994-12-22 Isis Pharmaceuticals, Inc. Oligomers for modulating ras oncogene
US5599917A (en) * 1994-03-17 1997-02-04 Pharmagenics, Inc. Inhibition of interferon-γ with oligonucleotides
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
ATE247128T1 (de) 1993-09-03 2003-08-15 Isis Pharmaceuticals Inc Aminoderivatisierte nukleoside und oligonukleoside
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
IL111105A (en) * 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
FR2710846B1 (fr) 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US8431119B2 (en) * 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5612212A (en) * 1993-11-12 1997-03-18 The University Of Pennsylvania Selective inhibition of cell proliferation by vav antisense oligonucleotides
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5814619A (en) * 1994-04-08 1998-09-29 Isis Pharmacuticals, Inc. Oligonucleotide inhibition of P120
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US20030069195A1 (en) * 1996-03-01 2003-04-10 Farrar Gwenyth Jane Suppression of polymorphic alleles
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
EP0938320B2 (de) * 1996-03-26 2014-06-18 Michael S. Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US8551970B2 (en) * 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
WO1998042722A1 (en) 1997-03-21 1998-10-01 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
EP1045918B1 (de) 1998-01-12 2008-08-20 Pedro Jose G protein-verwandte kinasemutanten in der essentiellen hypertonie
EP1080103A4 (de) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
AU772847B2 (en) 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
DE60028732T2 (de) 1999-02-25 2007-06-14 Exact Sciences Corp., Maynard Verfahren zur erhaltung der dns-integrität
ATE331811T1 (de) 1999-04-09 2006-07-15 Exact Sciences Corp Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
CA2394921A1 (en) * 1999-12-07 2001-06-14 Anthony P. Shuber Supracolonic aerodigestive neoplasm detection
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
EP1158055A1 (de) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Verfahren zur Diagnose von Krebs
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
CN1274072C (zh) * 2000-08-03 2006-09-06 松下电器产业株式会社 无刷电机及其制造方法
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US20110052546A1 (en) * 2000-09-19 2011-03-03 University Of South Florida Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
AU2002327308A1 (en) * 2001-07-25 2003-02-17 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
CA2474414C (en) * 2002-02-01 2018-03-06 Mcgill University Oligonucleotides comprising alternating segments and uses thereof
AU2003213107A1 (en) * 2002-02-15 2003-09-09 Exact Sciences Corporation Methods for analysis of molecular events
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US7635560B2 (en) * 2003-04-17 2009-12-22 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
ES2500921T3 (es) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células
CA2524883C (en) * 2003-05-16 2014-07-22 Universite Laval Potassium-chloride cotransporter kcc2 modulation for treatment of pain
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP1727556A2 (de) * 2004-02-17 2006-12-06 University Of South Florida Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
JP2007537167A (ja) * 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル ホスホリパーゼｃガンマの調節、並びにそれによる疼痛及び侵害受容の制御
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US7700272B2 (en) * 2004-06-09 2010-04-20 Mcgill University Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans
US7981607B2 (en) * 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2006135862A2 (en) * 2005-06-10 2006-12-21 Children's Hospital And Research Center At Oakland Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP2051585A4 (de) * 2006-04-28 2010-06-02 Univ South Florida Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
EP2057284A4 (de) * 2006-08-04 2011-06-29 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur modulation von jnk-proteinen
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US10035834B2 (en) 2008-06-18 2018-07-31 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
KR20110135938A (ko) 2009-02-13 2011-12-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 매트릭스 메탈로프로테이나제(ｍｍｐ)2 및 ｍｍｐ9를 억제하기 위한 화합물 및 방법
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
EP2476441A1 (de) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Verfahren und Reagenzien zur effizienten und gezielten Abgabe von therapeutischen Molekülen an CXCR4-Zellen
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR20170036142A (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
AU2014318545A1 (en) 2013-09-12 2016-03-24 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
HUE054204T2 (hu) 2014-09-05 2021-08-30 Rsem Lp Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
EP3302489A4 (de) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
BR112018007611A2 (pt) 2015-10-14 2018-10-23 Bio Path Holding Inc ácidos nucleicos p-etóxi para formulação lipossômica
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
BR112019005166A2 (pt) 2016-09-16 2019-07-02 Bio Path Holding Inc terapia de combinação com oligonucleotídeos antisense lipossômicos
MD3554553T2 (ro) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
JP7237009B2 (ja) 2017-04-19 2023-03-10 バイオ－パス ホールディングス， インコーポレイテッド Ｓｔａｔ３阻害のためのｐ－エトキシ核酸
US20210070845A1 (en) 2017-12-15 2021-03-11 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557870A1 (de) * 1975-12-22 1977-06-23 Linde Ag Verfahren und vorrichtung zum tiefgefrieren von biologischen substanzen
US4481946A (en) * 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4486188A (en) * 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
JPS61122215A (ja) * 1984-11-19 1986-06-10 Akira Kaji 制癌剤
WO1987003451A1 (en) * 1985-12-05 1987-06-18 Fred Hutchinson Cancer Research Center Anti-sense rna for treatment of retroviral disease states
FR2604438B1 (fr) * 1986-09-26 1988-12-23 Centre Nat Rech Scient Nouveaux conjugues de couplage entre des sequences d'arn ou d'adn et une proteine, leur procede de preparation et leur application biologique
GB8703451D0 (en) 1987-02-13 1987-03-18 Brennand R W Pond breather
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
JPH05500217A (ja) * 1989-09-01 1993-01-21 テンプル　ユニバーシティ　―　オブ　ザ　コモンウェルス　システム　オブ　ハイヤー　エデュケーション ｃ―ａｂｌプロト―オンコ遺伝子に対するアンチセンスオリゴヌクレオチド
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides

Also Published As

Publication number Publication date
WO1990009180A1 (en) 1990-08-23
DK0458829T3 (de) 1997-02-10
CA2046916A1 (en) 1990-08-16
JPH04505752A (ja) 1992-10-08
ES2094148T3 (es) 1997-01-16
CA2046916C (en) 2001-03-27
EP0458829B1 (de) 1996-09-25
AU5085690A (en) 1990-09-05
US5087617A (en) 1992-02-11
EP0458829A1 (de) 1991-12-04
DE69028694D1 (de) 1996-10-31
ATE143265T1 (de) 1996-10-15
AU635002B2 (en) 1993-03-11

Similar Documents

Publication Publication Date Title
DE69028694D1 (de) Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden
MY113490A (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
EP1059929A4 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
ATE236248T1 (de) Verfahren zur verwendung von oligonukleotiden mit modifizierten cpg dinukleosiden
ATE199741T1 (de) Gentherapeutische behandlung von tumoren mit einem endothelzellspezifischen, zellzyklusabhängigen wirkstoff
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
EP0161606A3 (en) Drug, and methods of preparing and using it for treatment of tumors
ATE88097T1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
ATE172099T1 (de) Implantierte vorrichtung mit tumorzellen zur behandlung von krebs
BR9607894A (pt) Processo para tratar tumores
ATE260666T1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE407677T1 (de) Gereinigte zubereitungen von 10-propargyl-10- deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
EP1171165A4 (de) Injektion von autologem knochenmark in den herzmuskel
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
PT1032429E (pt) Metodo para aplicacao de adn in vivo utilizando um aparelho sem agulha
ES2062517T3 (es) Quimioterapia local con 4-hidroperoxiciclofosfamida.
Haas et al. Autologous stem cell transplantation for chronic myeloid leukemia
RU99126204A (ru) Способ лечения рака легкого
TH51752B (th) องค์ประกอบของยาร่วมฤทธิ์และวิธีการสำหรับการบำบัดรักษาการเจริญเติบโตของเนื้องอกหรือมะเร็ง และสำหรับทำให้การสร้างเม็ดเลือดกลับดีขึ้น หรือการเพิ่มเม็ดเลือด
Hungate et al. Fully portable blood irradiator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee